176 related articles for article (PubMed ID: 7500912)
1. Intact antigen presentation for Epstein-Barr virus (EBV)-specific CTL by a lymphoblastoid cell line established from a patient with severe chronic active EBV infection.
Kimura H; Tsuge I; Imai S; Yamamoto M; Kuzushima K; Osato T; Morishima T
Med Microbiol Immunol; 1995 Aug; 184(2):63-8. PubMed ID: 7500912
[TBL] [Abstract][Full Text] [Related]
2. Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.
Kuzushima K; Yamamoto M; Kimura H; Ando Y; Kudo T; Tsuge I; Morishima T
Clin Exp Immunol; 1996 Feb; 103(2):192-8. PubMed ID: 8565299
[TBL] [Abstract][Full Text] [Related]
3. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
4. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.
Rickinson AB; Moss DJ
Annu Rev Immunol; 1997; 15():405-31. PubMed ID: 9143694
[TBL] [Abstract][Full Text] [Related]
5. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.
Tsuge I; Morishima T; Kimura H; Kuzushima K; Matsuoka H
J Med Virol; 2001 Jun; 64(2):141-8. PubMed ID: 11360246
[TBL] [Abstract][Full Text] [Related]
6. Identification of a cytotoxic T-lymphocyte response to the novel BARF0 protein of Epstein-Barr virus: a critical role for antigen expression.
Kienzle N; Sculley TB; Poulsen L; Buck M; Cross S; Raab-Traub N; Khanna R
J Virol; 1998 Aug; 72(8):6614-20. PubMed ID: 9658107
[TBL] [Abstract][Full Text] [Related]
7. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
Murray RJ; Kurilla MG; Brooks JM; Thomas WA; Rowe M; Kieff E; Rickinson AB
J Exp Med; 1992 Jul; 176(1):157-68. PubMed ID: 1319456
[TBL] [Abstract][Full Text] [Related]
8. Defective activity of Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes in children with chronic active EBV infection and in their parents.
Fujieda M; Wakiguchi H; Hisakawa H; Kubota H; Kurashige T
Acta Paediatr Jpn; 1993 Oct; 35(5):394-9. PubMed ID: 8256622
[TBL] [Abstract][Full Text] [Related]
9. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
10. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition.
Lee SP; Constandinou CM; Thomas WA; Croom-Carter D; Blake NW; Murray PG; Crocker J; Rickinson AB
Blood; 1998 Aug; 92(3):1020-30. PubMed ID: 9680372
[TBL] [Abstract][Full Text] [Related]
11. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance.
Khanna R; Burrows SR; Steigerwald-Mullen PM; Thomson SA; Kurilla MG; Moss DJ
Virology; 1995 Dec; 214(2):633-7. PubMed ID: 8553567
[TBL] [Abstract][Full Text] [Related]
12. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Epstein-Barr virus-associated cancers.
Rooney CM; Roskrow MA; Smith CA; Brenner MK; Heslop HE
J Natl Cancer Inst Monogr; 1998; (23):89-93. PubMed ID: 9709309
[TBL] [Abstract][Full Text] [Related]
14. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
15. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG; Small TN; Heller G; Dupont B; O'Reilly RJ
Blood; 1996 Mar; 87(6):2594-603. PubMed ID: 8630428
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
[TBL] [Abstract][Full Text] [Related]
17. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.
Silins SL; Cross SM; Elliott SL; Pye SJ; Burrows JM; Moss DJ; Misko IS
Int Immunol; 1997 Nov; 9(11):1745-55. PubMed ID: 9418135
[TBL] [Abstract][Full Text] [Related]
18. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
Khanna R; Burrows SR; Kurilla MG; Jacob CA; Misko IS; Sculley TB; Kieff E; Moss DJ
J Exp Med; 1992 Jul; 176(1):169-76. PubMed ID: 1377222
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
20. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.
Savoldo B; Huls MH; Liu Z; Okamura T; Volk HD; Reinke P; Sabat R; Babel N; Jones JF; Webster-Cyriaque J; Gee AP; Brenner MK; Heslop HE; Rooney CM
Blood; 2002 Dec; 100(12):4059-66. PubMed ID: 12393655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
